ISSN 2327-2236
Vol. 1, Issue 1, 2013May 24, 2013 EDT
The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
Articles in Vol. 1, Issue 1, 2013
Vol. 1, Issue 1, 2013
- Explaining Obesity- and Smoking-related Healthcare Costs through Unconditional Quantile RegressionBijan BorahJames NaessensKerry OlsenNilay Shah
- Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial FibrillationLi WangElyse FritschelOnur Baser
- Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in HungaryRaymond OdhiamboJagpreet ChhatwalShannon Allen FerranteAntoine El KhouryElamin Elbasha
- Generalized Propensity Score Matching with Multilevel Treatment OptionsOnur Baser
- Applied Comparison of Meta-analysis TechniquesLi WangColin Lewis-BeckElyse FritschelErdem BaserOnur Baser
- The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic MedicationChristian FroisThomas O’ConnellJacqueline PesaJohn Fastenau
1.
Frois C, O’Connell T, Pesa J, Fastenau J. The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication. JHEOR. 2013;1(1):54-61. doi:10.36469/9853
